Hosted on MSN29d
Bruker’s (NASDAQ:BRKR) Q4 Sales Top Estimates But Full-Year Sales Guidance Misses ExpectationsFor the fourth year in a row, Bruker has delivered well above-market organic and double-digit CER revenue growth. With approximately 70% cumulative revenue growth in the last four years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback